-
5/10/2024
Emergent BioSolutions Inc.announced that its2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday，May232024at9:00 am eastern time。
-
Despite the changing landscape in biopharma，many companies are still recruiting.If you’re looking to make a career change，here are 12biopharma companies hiring on BioSpace now。
-
5/1/2024
Emergent BioSolutions Inc.（NYSE:EBS）today reported financial results for the first quarter ended March312024。
-
5/1/2024
Emergent BioSolutions Inc.announced the results of anew national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students， and more than9in10parents in the survey agree schools should do more to educate on the risks of opioids and how to respond to an overdose。
-
5/1/2024
Emergent BioSolutions announced the next phase of its new operational plan that consolidates operations，closes several manufacturing faclities，and restructures its enterprise workforce to improve the performance and profitability of its business。
-
4/30/2024
Emergent BioSolutions Inc.announced that it has entered into a“Concent，Waiver and Seventh Amendment“to its existing credit facility。
-
4/22/2024
Emergent BioSolutions Inc.（NYSE:EBS）will host a conference call on Wednessday，May12024，at5:00pm eastern time to discuss the financial results for the first quarter2024，key business updates，revenue guidance for the second quarter of 2024，and financial outlook for full year2024.Conference Call Information Particpants can access the conference call live via webcast。
-
3/28/2024
Emergent BioSolutions Inc.remains committed to fighting the ongoing opioid crisis by broadening access to，and awareness of，NARCAN®Nasal Spray to help save lives in opioid overdose emergencies。
-
3/25/2024
Emergent BioSolutions Inc.announced that the U.S.Food and Drug Administration has listed“No Action Indicated”or NAI status classification for the company's Baltimore Bayview manufacturing facility。
-
3/6/2024
Emergent BioSolutions Inc.（NYSE:EBS）today reported financial results for the quarter and year ended December312023。
-
2/29/2024
Emergent BioSolutions Inc.will host a conference call on Wednesday，March62024,at5:00pm eastern time to discuss the financial results for the fourth quarter and full year2023。
-
2/21/2024
Emergent BioSolutions Inc.today announced that its Board of Directors has appointed Joseph C.Papa as president and CEO，effective February212024。
-
1/11/2024
Emergent BioSolutions Inc.（NYSE:EBS）today announced that it has secured an indefinite-delivery，indefinite-quantity（IDIQ）procurement contract with a maximum value up to$235.8million to supply BioThrax®（Anthrax Vaccine Adsorbed）foruse by all branches of the U.S.military as Pre-Exposure Prophylaxis（PrEP）for anthrax disease。
-
1/9/2024
Emergent BioSolutions today announced that Haywood Miller，Interim Chief Executive Officer and Rich Lindahl，Chief Financial Officer，will present at the 42nd Annual J.P.Morgan Healthcare Conference on Thursday，January112024，at9:00a.m.PT。
-
11/28/2023
Emergent BioSolutions Inc.（NYSE:EBS）today announced that the Biomedical Advanced Research and Development Authority（BARDA）within the Administration for Strategic Preparedness and Response at the United Stated Department of Health and Human Services has awarded a$75 million option to Emergent’s existing contract（HHSO 1000030）在新的许可证anthrax vaccine CYFENDUS™，™（Anthrax Vaccine Adsorbed，Adjuvanted）。
-
11/24/2023
Emergent BioSolutions Inc.（NYSE:EBS）today confirmed that on November162023，the New York Stock Exchange（NYSE）sent a notice that the company is not in compliance with Section802.01 Eof the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form10-Q for the quarended September2023。
-
11/8/2023
Emergent BioSolutions Inc.（NYSE:EBS）today reported selected financial results for the third quarter ended September302023。
-
10/30/2023
Emergent BioSolutions Inc.has rescheduled its conference call to Wednesday，November8，at5:00 pm eastern time to discuss the financial results for the third quarter of 2023，recent business developments，and financial outlook for full year2023。
-
10/19/2023
Emergent BioSolutions Inc.will host a conference call on Thursday，November2023，at5:00 pm eastern time to discuss the financial results for the third quarter of 2023，recent business developments，and financial outlook for full year2023。
-
8/30/2023
Emergent BioSolutions Inc.announced NARCAN®Naloxone HCl Nasal Spray4mg will be available on shelves nationwide and online beginning in September。
